Next-Generation Therapies
Accelerating research discoveries to the clinic.
Accelerating research discoveries to the clinic.
Childhood cancer differs from adult cancer, and using cancer treatments designed specifically for adults on children can be ineffective and harmful.
The Next-Generation Therapies Impact Program supports innovative research that can rapidly advance to clinical trials and benefit young cancer patients everywhere.
The program’s priorities include developing new and novel therapies for the deadliest and hard-to-treat types of childhood cancers, such as brain cancer, metastatic sarcoma, treatment-resistant leukaemia and other refractory cancers.
The Next-Generation Therapies Impact Program encourages cutting-edge research approaches such as AI-driven precision medicine, high-throughput drug screening and advanced disease modelling to identify unique targets to paediatric cancer.
Recognising the critical need for more treatments, the Children’s Cancer CoLab will fund research that repurposes and/or optimises existing cancer treatments for young cancer patients. This may include clinical trials that can support the rapid and efficient translation of promising therapies into clinical practice.
Projects that also harness our Innovation Accelerators are encouraged to apply, fostering a collaborative ecosystem that maximises impact.
Children’s Cancer CoLab is guided by scientific rigour across all our Impact Programs, and our comprehensive evaluation framework sets clear objectives to measure the impact of our funding. The potential impact resulting from our Next-Generation Therapies Impact Program is:
Identify new effective therapies that increase survival rates for childhood cancer.
Our program funding is allocated through a competitive process underpinned by robust expert review. We adopt scientific rigour to evaluate each proposal’s potential for impact and alignment with identified childhood cancer research and care priorities.
